Organix, Inc.

Based in Massachusetts, US, and co-founded by Raj K. Razdan (CEO, Retired 2009), Peter Meltzer (President & CEO, Retired 2018), and Howard Sard (Vice President, Retired 2021) in 1986, Organix, Inc. , is the company operating as Contract Research Organization (CRO). The firm was acquired in April 2022 by Symeres, a European CRO and Contract Development and Manufacturing Organization (CDMO).

As of August 2022, the company employs more than 40 Ph. D. chemists and is led by Anu Mahadevan, CEO, and Paul Blundell, President. Organix is a partner organization for contract research and development in all areas of organic and medicinal chemistry, specializing in lipids and small molecules.

The companies services include custom synthesis, contract R&D, custom polymer synthesis, analytical services, medicinal chemistry services at the discovery end of the drug development process, and products it provides include non-proprietary compounds that are standards, building blocks, and intermediates like lipids, general intermediates, aryltributylstannanes, chloroacetanilides, tryptamines, etc, only for research and development purposes supplied from milligram (mg) to multi-gram amount. The firm serves scientists in the biotech and pharmaceutical industry, academia, and government clients. The company generates its revenue by offering its organic chemistry services dedicated to the discovery and preclinical stage of the drug discovery value chain and selling its non-proprietary compound products at a price ranging from USD 120 (for 1 gm 2-CHLORO-4'-HYDROXY ACETANILIDE) to USD 5,000 (for 100 mg O-3062, LIPID 5). As of April 2022, the firm generated over USD 10 million per annum.

The April 2022 acquisition will help Organix to better serve its clients by providing additional access to state-of-the-art cGMP services.